ARS Pharmaceuticals, Inc (SPRY) - Net Assets
Based on the latest financial reports, ARS Pharmaceuticals, Inc (SPRY) has net assets worth $114.26 Million USD as of December 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($327.65 Million) and total liabilities ($213.39 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check ARS Pharmaceuticals, Inc liquid asset ratio to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $114.26 Million |
| % of Total Assets | 34.87% |
| Annual Growth Rate | 30.01% |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 53.58 |
ARS Pharmaceuticals, Inc - Net Assets Trend (2018–2025)
This chart illustrates how ARS Pharmaceuticals, Inc's net assets have evolved over time, based on quarterly financial data. Also explore ARS Pharmaceuticals, Inc total assets for the complete picture of this company's asset base.
Annual Net Assets for ARS Pharmaceuticals, Inc (2018–2025)
The table below shows the annual net assets of ARS Pharmaceuticals, Inc from 2018 to 2025. For live valuation and market cap data, see SPRY company net worth.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $114.26 Million | -55.51% |
| 2024-12-31 | $256.80 Million | +11.28% |
| 2023-12-31 | $230.76 Million | -15.44% |
| 2022-12-31 | $272.89 Million | +972.70% |
| 2021-12-31 | $-31.27 Million | -122.52% |
| 2020-12-31 | $-14.05 Million | -150.79% |
| 2019-12-31 | $-5.60 Million | -130.79% |
| 2018-12-31 | $18.20 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to ARS Pharmaceuticals, Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 25478300000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $10.00K | 0.01% |
| Other Comprehensive Income | $125.00K | 0.11% |
| Other Components | $408.73 Million | 357.72% |
| Total Equity | $114.26 Million | 100.00% |
ARS Pharmaceuticals, Inc Competitors by Market Cap
The table below lists competitors of ARS Pharmaceuticals, Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Black Diamond Group Limited
TO:BDI
|
$813.30 Million |
|
Zhongyin Babi Food Co. Ltd.
SHG:605338
|
$813.30 Million |
|
Zhangjiagang Furui Special Equip
SHE:300228
|
$813.90 Million |
|
XPLR Infrastructure LP Unit
NYSE:XIFR
|
$814.05 Million |
|
Besalco Sa
SN:BESALCO
|
$813.18 Million |
|
Quanex Building Products
NYSE:NX
|
$813.11 Million |
|
Wecome Intelligent Manufacturing Co. Ltd.
SHG:603070
|
$812.70 Million |
|
MetroCity Bankshares
NASDAQ:MCBS
|
$812.67 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in ARS Pharmaceuticals, Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 256,798,000 to 114,258,000, a change of -142,540,000 (-55.5%).
- Net loss of 171,298,000 reduced equity.
- Other comprehensive income decreased equity by 95,000.
- Other factors increased equity by 28,853,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-171.30 Million | -149.92% |
| Other Comprehensive Income | $-95.00K | -0.08% |
| Other Changes | $28.85 Million | +25.25% |
| Total Change | $- | -55.51% |
Book Value vs Market Value Analysis
This analysis compares ARS Pharmaceuticals, Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 7.38x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 15.55x to 7.38x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2018-12-31 | $0.55 | $8.56 | x |
| 2019-12-31 | $-0.17 | $8.56 | x |
| 2020-12-31 | $-0.40 | $8.56 | x |
| 2021-12-31 | $-1.08 | $8.56 | x |
| 2022-12-31 | $6.83 | $8.56 | x |
| 2023-12-31 | $2.42 | $8.56 | x |
| 2024-12-31 | $2.51 | $8.56 | x |
| 2025-12-31 | $1.16 | $8.56 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently ARS Pharmaceuticals, Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -149.92%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -203.25%
- • Asset Turnover: 0.26x
- • Equity Multiplier: 2.87x
- Recent ROE (-149.92%) is below the historical average (-34.96%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2018 | -96.60% | 0.00% | 0.00x | 1.51x | $-19.40 Million |
| 2019 | 0.00% | 0.00% | 0.00x | 0.00x | $-23.41 Million |
| 2020 | 0.00% | -5.97% | 0.68x | 0.00x | $340.20K |
| 2021 | 0.00% | -367.65% | 0.09x | 0.00x | $-17.12 Million |
| 2022 | -12.71% | -2635.41% | 0.00x | 1.03x | $-61.97 Million |
| 2023 | -23.56% | -181216.67% | 0.00x | 1.01x | $-77.44 Million |
| 2024 | 3.11% | 8.97% | 0.25x | 1.37x | $-17.68 Million |
| 2025 | -149.92% | -203.25% | 0.26x | 2.87x | $-182.72 Million |
Industry Comparison
This section compares ARS Pharmaceuticals, Inc's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $248,191,134
- Average return on equity (ROE) among peers: -119.98%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| ARS Pharmaceuticals, Inc (SPRY) | $114.26 Million | -96.60% | 1.87x | $813.24 Million |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-34.80 Million | 0.00% | 0.00x | $118.88 Million |
| Abcellera Biologics Inc (ABCL) | $1.15 Billion | -12.70% | 0.29x | $1.07 Billion |
| Abeona Therapeutics Inc (ABEO) | $134.04 Million | -42.28% | 0.30x | $292.09 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $266.97 Million | -19.62% | 0.16x | $171.87 Million |
| Abpro Holdings, Inc. (ABP) | $-14.95 Million | 0.00% | 0.00x | $448.19K |
| Absci Corp (ABSI) | $274.41 Million | -38.23% | 0.17x | $345.85 Million |
| Arbutus Biopharma Corp (ABUS) | $169.44 Million | -45.00% | 0.21x | $840.56 Million |
| ABVC Biopharma Inc (ABVC) | $8.87 Million | -144.74% | 0.54x | $26.41 Million |
| Abivax SA American Depositary Shares (ABVX) | $7.19 Million | -844.90% | 9.51x | $9.33 Billion |
| ACADIA Pharmaceuticals Inc (ACAD) | $518.41 Million | -52.35% | 0.08x | $3.74 Billion |
About ARS Pharmaceuticals, Inc
ARS Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes treatments for severe allergic reactions in the United States and internationally. The company is involved in the development of neffy, a needle-free intranasal delivery of epinephrine for emergency treatment of Type I allergic reactions, including anaphylaxis. ARS Pharmaceuticals, Inc. was founded in 2015 and is … Read more